SPONSOR
SWOG Cancer Research Network
Total Trials
9
Recruiting
9
Phases
Phase 3, Phase 2, Phase 3, Phase 2
Conditions studied: Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu NegativeProgesterone Receptor PositivePrognostic Stage IV Breast Cancer AJCC v8Elevated CA15-3 or CEA or CA27-29Malignant Solid NeoplasmLocally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8
SWOG Cancer Research Network is a clinical research sponsor with 9 registered studies on ClinicalTrials.gov, of which 9 are actively recruiting participants. Research covers conditions including Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive.
The trial portfolio spans Phase 3, Phase 2, Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — SWOG Cancer Research Network
How many clinical trials has SWOG Cancer Research Network sponsored?
ClinicalMetric currently tracks 9 clinical trials sponsored by SWOG Cancer Research Network, of which 9 are actively recruiting participants. These trials cover conditions including Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does SWOG Cancer Research Network research focus on?
SWOG Cancer Research Network clinical trials span Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, and additional conditions. The research pipeline includes Phase 3, Phase 2, Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a SWOG Cancer Research Network clinical trial?
To participate in a SWOG Cancer Research Network trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all SWOG Cancer Research Network trials with current recruitment status updated daily.
Clinical Trials by SWOG Cancer Research Network
NCT03723928
Recruiting
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
Anatomic Stage IV Breast Cancer AJCC v8
NCT04871542
Recruiting
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
NCT06998940 Phase 3
Recruiting
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Locally Advanced Pancreatic Adenocarcinoma
NCT06616584 Phase 2, Phase 3
Recruiting
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Recurrent Lung Non-Small Cell Carcinoma
NCT07018869 Phase 3
Recruiting
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
Colorectal Cancer Stage II
NCT07278739
Recruiting
Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams
Malignant Solid Neoplasm
NCT05642611 Phase 3
Recruiting
Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Malignant Solid Neoplasm
NCT06116682 Phase 2
Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Lung Non-Small Cell Carcinoma
NCT06022939 Phase 3
Recruiting
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
AL Amyloidosis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology